Helsinn And BridgeBio Ink Infigratinib Cancer Pact
Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology
Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.
You may also be interested in...
Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.
Russian sovereign wealth fund and Sputnik V vaccine producer RDIF has teamed up with the country’s biggest bank to fund ‘home-grown’ tech and science-intensive start-ups.
AstraZeneca's partner FibroGen stunned investors and regulators by announcing that previously disclosed cardiovascular safety data for CKD candidate roxadustat included changes made post hoc, rather than as pre-specified with the US FDA.